作者机构:
[孟蕾; 邓凯文; 潘雪; 陈定芳; 吴月峰; 肖美凤; 李海英; 王韧; 贺福元; 周逸群] School of Pharmacy Hunan Provincial Key Laboratory of Drugability and Preparation Modification of Traditional Chinese Medicine, Supramolecular Mechanism and Mathematic-physics Chracterization for Chinese Materia Medica, Hunan University of Chinese Medicine, Changsha, 410208, China
通讯机构:
[Pan, X.; He, F.-Y.] S;School of Pharmacy Hunan Provincial Key Laboratory of Drugability and Preparation Modification of Traditional Chinese Medicine, China
作者机构:
[陈祥宇; 阳晶晶; 梅志刚] Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, 410208, China;[张文丽] School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, China
通讯机构:
[Mei, Z.-G.] K;[Zhang, W.-L.] S;Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, China;School of Pharmacy, China
作者机构:
[Lyu M.-Y.; 邱伊星; 王炜; 彭彩云; 袁汉文; 罗江溢] TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Material Medical Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, China;Hunan Institute for Food and Drug Control, Changsha, 410001, China;[刘杨] TCM and Ethnomedicine Innovation & Development International Laboratory, Innovative Material Medical Research Institute, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, China, Hunan Institute for Food and Drug Control, Changsha, 410001, China
通讯机构:
[Peng, C.-Y.; Wang, W.] T;TCM and Ethnomedicine Innovation & Development International Laboratory, China
作者机构:
[吴月峰; 贺福元; 潘雪; 李海英; 周燕子; 王敏存; 陈定芳; 杨岩涛] College of Pharmacy, Hunan University of Chinese Medicine, Hunan Provincial Key Laboratory of Druggability and Preparation Modification for Chinese Materia Medica, Laboratory of Supramolecular Mechanism and Mathematic-physics Characterization of Traditional Chinese Medicine (TCM), Property and Pharmacodynamic Key Laboratory of TCM, National Administration of TCM State KeyLaboratoryof Chinese Materia Medica Intelligence and Drug Innovation (Cultivation), Changsha, 410208, China;[邓凯文] The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China
摘要:
Objective:To study the effect of effective components of Yixintai(益心泰)on left ventricular hypertrophy and cardiomyocyte apoptosis in rabbits with chronic heart failure(CHF)and its mechanism.Methods:Twenty New Zealand rabbits were randomLy selected from 120 rabbits as th...MORE Objective:To study the effect of effective components of Yixintai(益心泰)on left ventricular hypertrophy and cardiomyocyte apoptosis in rabbits with chronic heart failure(CHF)and its mechanism.Methods:Twenty New Zealand rabbits were randomLy selected from 120 rabbits as the sham operation group,and the remaining 100 rabbits were used to establish the rabbit model of CHF by coarctation of the abdominal aorta and intragastric administration of propylthiouracil.The rabbits successfμLly modeled were randomLy divided into a model control group,2.1 g/kg,4.2 g/kg,and 8.4 g/kg of Yixintai effective components groups,and a 2.75 mg/kg losartan potassium group.An equal volume of distilled water was orally administrated to rabbits in the model control group and sham operation control group,once per day,for 4 weeks.After treatment,the myocardial pathological structure,the level of N-terminal B-type natriuretic peptide(NT-pro BNP)in the serum,cardiacμLtrasound parameters,hemodynamic parameters,left ventricular mass index,cardiomyocyte apoptosis,and the protein and mRNA expression levels of c-Jun N-terminal kinase(Cjun),serum response element(Cfos)in myocardial tissues were observed.Results:As compared with the sham operation group,the serum level of NT-pro BNP in the model control group was significantly increased(P<0.01),the left ventricular ejection fraction(LVEF)and the left ventricular systolic pressure(LVSP)were decreased(P<0.01),the left ventricular posterior wall thickness(LVPWT)and the left ventricular end-diastolic pressure(LVEDP)were increased(P<0.01),the left ventricular mass index and the cardiomyocyte apoptosis were increased(P<0.01),and the protein and mRNA expression of Cjun and Cfos in myocardial tissues were up-regulated(P<0.01).As compared with the model control group,the serum level of NT-pro BNP in each treatment group was significantly decreased(P<0.01),the LVEF and the LVSP were increased(P<0.01),the LVPWT and the LVEDP were decreased(P<0.01),the cardiomyocyte apoptosis were decreased(P<0.01),and the protein and mRNA expression of Cjun and Cfos in myocardial tissues were down-regulated(P<0.05,P<0.01).The left ventricular mass index in the 2.75 mg/kg losartan potassium group and 4.2 g/kg and 8.4 g/kg of Yixintai effective components groups were significantly decreased(P<0.01).Conclusion:The effective components of Yixintai can inhibit the protein and mRNA expressions of Cjun and Cfos in myocardial tissues of rabbits with CHF,reduce left ventricular hypertrophy and cardiomyocyte apoptosis,and improve heart failure.FEWER